Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Dec 19 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 4 pages · English

Summary by 6ix AI

The agreement includes the introduction of several tests aimed at improving cancer care and personalized treatment options for patients. This collaboration is expected to enhance access to precision oncology and support clinicians in making informed treatment decisions. The press release outlines the significance of these tests in identifying hereditary cancer risks and aiding in disease management.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 19, 2025, titled "Zydus Lifesciences Limited signs an exclusive agreement with Myriad Genetics of US to launch cancer-risk assessment diagnostic tests in India".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases